Biogen to Karyopharm Therapeutics
The patent portfolio encompasses innovative orally acceptable dosage forms and therapeutic methods utilizing specific compounds targeting neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's disease. Key innovations include structurally diverse compounds, with various alkyl, heterocyclyl, and heteroaryl substitutions, offering potential as effective treatments by ensuring improved bioavailability and selective targeting of neurodegenerative pathways. These contributions may lead to significant advancements in the management of debilitating neurological conditions.
Breadth Distribution
Complexity Distribution
Enforceability Distribution
Infringement Distribution
Patents
| Patent Number | Summary | Breadth | Complexity | Enforceability | Infringement |
|---|---|---|---|---|---|
| 11602530 | This patent protects a method for treating epilepsy by administering a specified compound or its pharmaceutically acceptable variants, enhancing therapeutic options for patients suffering from this condition. |
C
|
A
|
C
|
- |
| 11318120 | Patent 11318120 protects a novel method for synthesizing (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N′-pivaloylacrylohydrazide through a series of chemical reactions starting from (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate, utilizing various reagents including LiOH and hydrazine hydrate to create the desired compound efficiently. |
D
|
D
|
D
|
- |
| 10925859 | This patent protects an orally acceptable dosage form containing a specified compound capable of penetrating the blood-brain barrier, designed to treat various CRM1 mediated disorders, with versatility in formulation types, including immediate, sustained, and delayed release forms. |
C
|
D
|
C
|
- |
| 10722497 | Patent 10722497 protects a range of compounds with defined structural formulas and various substituent groups that are designed to inhibit CRM1 activity, providing therapeutic methods for treating disorders associated with CRM1 including proliferative and autoimmune disorders. |
C
|
D
|
C
|
- |
| 10617677 | The patent protects methods of treating neurodegenerative diseases, viral infections, and inflammatory diseases through the administration of specific compounds characterized by a defined structural formula, which has multiple substituent options, highlighting their therapeutic potential against conditions such as Alzheimer's, Parkinson's, and various viral pathogens. |
C
|
C
|
C
|
- |
| 10335393 | Patent 10335393 protects novel compounds with specific structural formulas and their pharmaceutical compositions, which are designed for treating disorders related to CRM1 activity, such as lupus and amyotrophic lateral sclerosis, highlighting unique substituents and configurations to enhance therapeutic efficacy. |
C
|
C
|
D
|
- |
| 10058535 | This patent protects a method for treating amyotrophic lateral sclerosis by orally administering a therapeutically effective amount of a specific compound or its pharmaceutically acceptable salt. |
C
|
A
|
D
|
- |
Patent Details
11602530
- CRM1 inhibitors for treating epilepsy
Published: 2023-03-14
This patent protects a method for treating epilepsy by administering a specified compound or its pharmaceutically acceptable variants, enhancing therapeutic options for patients suffering from this condition.
C
Breadth
A
Complexity
C
Enforceability
Claims
Infringement Analysis
11318120
- Nuclear transport modulators and uses thereof
Published: 2022-05-03
Patent 11318120 protects a novel method for synthesizing (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N′-pivaloylacrylohydrazide through a series of chemical reactions starting from (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate, utilizing various reagents including LiOH and hydrazine hydrate to create the desired compound efficiently.
D
Breadth
D
Complexity
D
Enforceability
Claims
Infringement Analysis
10925859
- Nuclear transport modulators and uses thereof
Published: 2021-02-23
This patent protects an orally acceptable dosage form containing a specified compound capable of penetrating the blood-brain barrier, designed to treat various CRM1 mediated disorders, with versatility in formulation types, including immediate, sustained, and delayed release forms.
C
Breadth
D
Complexity
C
Enforceability
Claims
Infringement Analysis
10722497
- Nuclear transport modulators and uses thereof
Published: 2020-07-28
Patent 10722497 protects a range of compounds with defined structural formulas and various substituent groups that are designed to inhibit CRM1 activity, providing therapeutic methods for treating disorders associated with CRM1 including proliferative and autoimmune disorders.
C
Breadth
D
Complexity
C
Enforceability
Claims
Infringement Analysis
10617677
- Nuclear transport modulators and uses thereof
Published: 2020-04-14
The patent protects methods of treating neurodegenerative diseases, viral infections, and inflammatory diseases through the administration of specific compounds characterized by a defined structural formula, which has multiple substituent options, highlighting their therapeutic potential against conditions such as Alzheimer's, Parkinson's, and various viral pathogens.
C
Breadth
C
Complexity
C
Enforceability
Claims
Infringement Analysis
10335393
- Nuclear transport modulators and uses thereof
Published: 2019-07-02
Patent 10335393 protects novel compounds with specific structural formulas and their pharmaceutical compositions, which are designed for treating disorders related to CRM1 activity, such as lupus and amyotrophic lateral sclerosis, highlighting unique substituents and configurations to enhance therapeutic efficacy.
C
Breadth
C
Complexity
D
Enforceability
Claims
Infringement Analysis
10058535
- Nuclear transport modulators and uses thereof
Published: 2018-08-28
This patent protects a method for treating amyotrophic lateral sclerosis by orally administering a therapeutically effective amount of a specific compound or its pharmaceutically acceptable salt.
C
Breadth
A
Complexity
D
Enforceability
Claims
Infringement Analysis